Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
原文: https://www.cnbc.com/2026/09/08/novartis-cholesterol-setback-drug-race-eli-lilly-amgen.html
Last Update:
8 9 月, 2026
